Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05116189
Title Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.

ovary epithelial cancer

fallopian tube carcinoma

peritoneal carcinoma


Bevacizumab + Docetaxel

Bevacizumab + Paclitaxel + Pembrolizumab

Bevacizumab + Docetaxel + Pembrolizumab

Bevacizumab + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | DEU | CAN | BEL

No variant requirements are available.